Liquid chromatography reveals AGEs as biomarkers for MS

Analysis conducted using liquid chromatography with tandem mass spectrometry (LC-MS-MS) has indicated that advanced glycation end products (AGEs) can act as biomarkers for the presence of multiple sclerosis (MS) in patients.

Comparison carried out with LC-MS-MS looked at the presence of the AGEs N-(Carboxymethyl)lysine (CML) and N-(Carboxyethyl)lysine (CEL) in MS patients and a healthy control group.

A significantly higher plasma level of CEL was seen in MS patients, although no significant difference was detected in CML levels.

However, the researchers conclude that CEL in particular and AGEs in general may both represent further investigative avenues for the discovery of MS biomarkers.

The team working on the project included representatives of the Jacobs Neurological Institute and the Biopolymer & Proteomics Resources Roswell Park Cancer Institute in Buffalo, along with the Kinkel Neurologic Center in Williamsville.

Findings were published in the Journal of Neuroinflammation, which carries research reports on all elements of the central nervous system's innate immunological responses.